0000000001190926
AUTHOR
Jc Chen
Rates, polarizations, and asymmetries in charmless vector-vector B meson decays
With a sample of approximately 89 million BBbar pairs collected with the BABAR detector, we perform a search for B meson decays into pairs of charmless vector mesons (phi, rho, and K*). We measure the branching fractions, determine the degree of longitudinal polarization, and search for CP violation asymmetries in the processes B->phiK*+, B->phiK*0, B->rho0K*+, and B->rho0rho+. We also set an upper limit on the branching fraction for the decay B->rho0rho0.
Searches for B0 decays to combinations of charmless isoscalar mesons
We search for B meson decays into two-body combinations of eta, eta', omega, and phi mesons from 89 million B B-bar pairs collected with the BaBar detector at the PEP-II asymmetric-energy e+e- collider at SLAC. We find the branching fraction BF(B0 -> eta omega) = (4.0^{+1.3}_{-1.2} +- 0.4) x 10^-6 with a significance of 4.3 sigma. For all the other decay modes we set the following 90% confidence level upper limits on the branching fractions, in units of 10^-6 : BF(B0 -> eta eta)<2.8, BF(B0 -> eta eta')<4.6, BF(B0 -> eta' eta')<10, BF(B0 -> eta'omega)<2.8, BF(B0 -> eta phi)<1.0, BF(B0 -> eta' phi)<4.5, BF(B0 -> phi phi)<1.5.
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…